8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): September 22, 2021

USA

EQUITIES CORP.

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

Delaware	30-1104301
(State<br><br> <br>of<br> Incorporation)	(I.R.S.<br> Employer<br><br> <br>Identification<br> No.)
901<br> Northpoint Parkway Suite 302 West Palm Beach<br><br> <br>FL<br> 33407	33407
(Address<br> of Principal Executive Offices)	(ZIP<br> Code)

Registrant’s telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securitiesregistered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	USAQ	OTCMKTS

Item7.01 Regulation FD Disclosure.

We are furnishing this Current Report on Form 8-K to furnish materials that will be provided at meetings with institutional investors or analysts. The materials are attached as Exhibit 99.1 to this Current Report on Form 8-K, are incorporated into this Item 7.01 by reference and are available on our investor relations website at usaqcorp.com. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing, or other means.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

ITEM9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Press<br> release dated September 22, 2021 entitled “USA Equities Corp. Provides Updated Investor and Shareholder Presentation<br> September 2021.”
99.2	USA Equities Corp Investor Presentation Slides - September 2021
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

---

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:<br> September 22, 2021
USA<br> Equities Corp.
	/s/ Troy Grogan
Name:	Troy<br> Grogan
Title:	CEO<br> and Chairman

EXHIBIT99.1

USAEquities Corp. Issues Updated September 2021 Investor Presentation

●	Superior<br> Business Model and Strategic Position Validated By Growing Client Base and Product Portfolio
●	Addressable<br> Market Opportunity Includes Over 250,000 Independent Primary Care Physicians
●	Favorably<br> Aligned with Industry Drivers Including Increasing Acceptance of Digital Medicine and Virtual Care Services by Third Party Payers
●	Active<br> Pipeline of New Product Growth Opportunities To Leverage Across Expanding Distribution Network and Customer Footprint
●	Successful<br> Capital Raise Increases Financial Flexibility to Execute on Growth Strategy

West Palm Beach, FL – September 22, 2021 – USA Equities Corp. (OTCQB: USAQ), a company focused on increasing physician revenues through value-based healthcare solutions and physician-directed digital medicine, today announced that it added a comprehensive investor presentation to the Company’s website highlighting USAQ’s growth strategy, recent milestones, key accomplishments and detailed discussion of product technology and business model.

The Company’s share price as of the close of business September 21, 2021 was $0.78 per share, Litchfield Hills Research has an investment rating of Buy on USAQ with a target price of $5 per share and views the stock as inexpensive on an absolute and relative basis. The market cap is currently at a low of $6.8 million compared to many peer companies with $50-100 million market capitalization.

“Our AllergiEnd® product portfolio continues to resonate in the physician market place with a growing customer base and strong value proposition. I am very excited about the future prospects for USA Equities and believe we offer a compelling and undervalued investment opportunity given our proprietary targeted solutions and sizable and growing addressable markets,” stated USAQ Chief Executive Officer Troy Grogan.

“Our market opportunity is comprised of over 250,000 independent U.S. primary care physicians. There are also over sixty million Americans with allergic disorders with an expected decline in the number of full-time-equivalent allergists and immunologists, but increasing patient demand. From an industry perspective, the COVID-19 pandemic has also heightened the need for and acceptance of digital medicine and reliance on virtual care, a trend on which our business model is strongly aligned with.

“Our visibility in the investment community is also increasing. In August, we announced a successful capital raise of $750,000 from an institutional investment fund. The proceeds will be focused on accelerating the growth of our medical practitioner customer base and expanding our portfolio of digital medicine applications” concluded Grogan. The following are some of the items discussed in the investor presentation, which can be accessed by going to https://www.usaqcorp.com/presentations:

●	Key<br> company milestones highlighting significant financial and strategic progress over the past year;
●	Detailed<br> discussion of proprietary AllergiEnd® product<br> line including FDA-cleared diagnostic equipment and products allowing primary care providers to diagnose and treat many common chronic<br> allergies in their offices;
●	Highlights<br> of QHSLab, a cloud-based<br> software and IT system that scales to allow a virtually unlimited number of user sessions to be activated with high availability<br> in most geographic regions;
●	Profiles<br> of USAQ’s management and medical advisory team which has a synergistic mix of industry experience, including comprehensive<br> medical manufacturing and business development backgrounds; and
●	Discussion<br> of alignment with industry growth drivers including significantly underserved U.S. allergy patient base, increasing acceptance of<br> telemedicine by third party payers and aging population with rising health needs

AboutUSA Equities Corp.

USA Equities Corp. (OTCQB: USAQ) is a medical device company providing digital medicine solutions and point of care diagnostic tests to primary care physicians. Digital medicine allows doctors to quickly and effectively assess their patients’ response to healthcare screening using advanced artificial intelligence algorithms. Digital medicine can also remotely monitor patients’ vital signs and evaluate the effects of newly prescribed medicines and treatments on their patients’ health through real time data that is transferred from patient to doctor. USAQ also markets and sells point of care, rapid response diagnostic tests which are used in the primary care practice. USAQ’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the service revenues of their practice.

For additional information, visit the Company’s website at www.USAQCorp.com

Forward-LookingStatements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor & Media Contact:
Olivia<br> Giamanco
USA<br> Equities Corp
(929)<br> 379-6503
IR@USAQCORP.COM

EXHIBIT 99.2